SELLAS Life Sciences (SLS) Operating Expenses (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Operating Expenses data on file, last reported at $9.3 million in Q1 2026.

• Quarterly Operating Expenses rose 52.6% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.5 million (up 12.65% YoY) and the FY2025 annual result came in at $28.3 million, down 10.28% from the prior year.
• Operating Expenses improved to $9.3 million in Q1 2026 per SLS's latest filing, from $8.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $17.7 million in Q1 2022 and bottomed at $6.1 million in Q1 2025.
• The 5-year median for Operating Expenses is $8.3 million (2025), against an average of $8.8 million.
• The widest annual swing landed in 2022, when Operating Expenses jumped 123.22%; it then sank 37.14% in 2025.
• Tracing SLS's Operating Expenses over 5 years: stood at $9.4 million in 2022, then fell by 13.43% to $8.2 million in 2023, then fell by 15.4% to $6.9 million in 2024, then climbed by 19.33% to $8.3 million in 2025, then grew by 12.08% to $9.3 million in 2026.
• Per Business Quant, the three latest SLS Operating Expenses figures stand at $9.3 million (Q1 2026), $8.3 million (Q4 2025), and $7.1 million (Q3 2025).

Peer Comparison